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Abstract
Background: Recent studies have provided evidence for a link between leptin and tumor necrosis
factor-alpha (TNF-α). Insulin-like growth factor I (IGF-I) mediates the metabolic effects of growth
hormone (GH). The GH axis is believed to be suppressed in chronic obstructive pulmonary disease
(COPD). The aim of this study is to find out whether acute exacerbations of COPD are followed
by changes in plasma leptin and insulin-like growth factor I (IGF-I) levels and furthermore, whether
these changes are related to systemic inflammation.
Methods: We measured serum leptin, IGF-I, TNF-α, interleukin 1β (IL-1β), interleukin 6 (IL-6) and
interleukin 8 (IL-8) levels in 52 COPD patients with acute exacerbation on admission to hospital
(Day 1) and two weeks later (Day 15). 25 healthy age-matched subjects served as controls. COPD
patients were also divided into two subgroups (29 with chronic bronchitis and 23 with
emphysema). Serum leptin and IGF-I were measured by radioimmunoassay and TNF-α, IL-1β, IL-6
and IL-8 were measured by ELISA.
Results: Serum leptin levels were significantly higher and serum IGF-I levels significantly lower in
COPD patients on Day 1 than in healthy controls (p < 0.001). A positive correlation was observed
between leptin and TNF-α on Day 1 (r = 0.620, p < 0.001). Emphysematous patients had
significantly lower IGF-I levels compared to those with chronic bronchitis both on Day 1 and Day
15 (p = 0.003 and p < 0.001 respectively).
Conclusion: Inappropriately increased circulating leptin levels along with decreased IGF-I levels
occured during acute exacerbations of COPD. Compared to chronic bronchitis, patients with
emphysema had lower circulating IGF-I levels both at the onset of the exacerbation and two weeks
later.
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Background
Weight loss commonly occurs in patients with chronic
obstructive pulmonary disease (COPD) [1]. In a subgroup
of COPD patients, weight loss is suggested to follow a
stepwise pattern related to acute disease exacerbations [2].
Recently, cytokine-mediated metabolic derangements
have been considered to be among the candidates respon-
sible for weight loss in COPD patients [3,4]. It has been
shown that tumor necrosis factor-α (TNF-α) circulating
levels are increased in weight-losing COPD patients [3,4].
COPD is characterized by a systemic inflammatory
response that may be even more pronounced during an
acute exacerbation of COPD [5].
Leptin, a protein synthesized by adipose tissue and
encoded by the ob gene plays an important role in the
energy balance and its circulating concentrations are pro-
portional to the amount of fat mass (FM). Inappropriately
increased leptin levels are thought to induce metabolic
effects underlying anorexia and loss of body weight in
chronic diseases including COPD [6,7]. Administration of
endotoxin or cytokines such as TNF-α or IL-1 produced a
prompt and dose-dependent increase in serum leptin lev-
els in both experimental animals [8] and humans [9]. In
stable patients with emphysema, leptin was found to be
positively related to plasma soluble TNF-receptor 55 [5].
The observed link between inflammatory cytokines and
leptin led to the hypothesis that adipose tissue gene
expression is regulated by inflammatory cytokines, which
in turn could induce anorexia in acute or chronic inflam-
mation.
Growth hormone (GH) is secreted by the anterior pitui-
tary and mediates its major metabolic effects through acti-
vation of somatomedins, predominantly insulin-like
growth factor I (IGF-I) [10]. In COPD, little is known
about circulating GH or IGF-I concentrations. Some
authors found a decrease in GH or IGF-I, others an
increase [11]. IGF-I levels tended to be lower in stable and
hospitalized COPD patients due to an exacerbation [12].
IGF-I mRNA levels were decreased in muscle biopsies
from hospitalized patients due to an acute exacerbation of
COPD [13]. In animal studies, recombinant IGF-I has
been shown to ameliorate the protein catabolism and
promote anabolism observed under hypoxic conditions
[14]. However, daily administration of rGH increased
lean body mass but did not improve muscle strength in
COPD patients [15].
In our study, we measured cytokine (TNF-α, IL-1β, IL-6
and IL-8), leptin and IGF-I levels at the onset of a COPD
exacerbation as well as 15 days later. The aim of this study
was to elucidate two questions. Firstly, whether COPD
exacerbations are accompanied by changes in circulating
levels of leptin and IGF-I. Secondly, whether plasma IGF-
I and leptin levels are related to those of cytokines as a
possible reflection of the enhanced inflammatory status
observed during a COPD exacerbation.
Methods
Patients
The patient group consisted of subjects consecutively
admitted to our department due to an infectious exacerba-
tion of COPD. COPD was defined according to GOLD cri-
teria [16]. Irreversible chronic airflow obstruction was
confirmed, i.e., < 10% improvement in FEV1 expressed as
percentage of predicted after inhalation of a β2-agonist.
An infectious exacerbation of COPD was defined when at
least two of the following three criteria were fulfilled: (a)
recent increase in dyspnea (b) increased sputum volume
and (c) sputum purulence, provided that one of the two
criteria is purulent sputum [16].
All patients were current or ex-smokers. Patients with a
medical history of comorbid diseases, such as diabetes
mellitus, heart failure, lung cancer, collagen vascular dis-
ease or disturbances of thyroid function were excluded
from the study. The final study group consisted of 52
patients (43 men, 9 women). The patients were treated
with a standard protocol of medication consisting of neb-
ulized short-acting β2-sympathicomimetics (salbutamol),
inhaled anticholinergics (ipratropium bromide) and
intravenously administered prednisolone. Prednisolone
was given in the same dose (50 mg) for 7 days and then
directly stopped, without tapering the dose. Antibiotic
treatment was given to all COPD patients for 7 days. Dur-
ing hospitalization 38 of the 52 patients received supple-
mental oxygen therapy, according to measured arterial
blood gases.
The control group consisted of 25 healthy age-matched
adults (19 men, 6 women). They had no medical illnesses,
had normal physical examinations, blood counts, chem-
istries and showed no symptoms or signs of infection at
the time of the study.
All participants were informed in detail of the characteris-
tics of the study and written consent was obtained. The
study was approved by the ethics committee of our hospi-
tal.
Body composition
Body height was determined to the nearest 0.5 cm with
subjects standing barefoot. Body weight was assessed to
the nearest 0.1 kg by using a digital weighing chair while
subjects wore light clothing and no shoes. Body mass
index (BMI) was calculated according to the equation BMI
= Weight (kg)/Height2 (cm2). Fat mass (FM) was meas-
ured with bioelectric impedance analysis with the porta-
ble device OMRON BF 302, (OMRON Healthcare EuropeBMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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B.V, Hoofddorp). The basic principles of bioelectric
impedance analysis were described by Lukaski and col-
leagues [17].
Lung function
FEV1 and FVC were measured with standard spirometric
techniques (SPIRO 232 MORGAN, Model 435 P.K MOR-
GAN, Ltd. Gillingham, Kent, England). Arterial blood
gases were obtained once in healthy individuals and twice
in COPD patients (upon admission and after 15 days)
with the subject in the sitting position and breathing
ambient air. Lung function values were expressed as a per-
centage of predicted [18]. Arterial blood gases were ana-
lysed on a blood gas analyzer (Rapidlab 855, Bayer
Healthcare LLC Diagnostics Division, NY 10591, USA).
Assessment of emphysema
The distinction between COPD patients with predomi-
nant emphysema and those with chronic bronchitis was
based mainly on high-resolution computed tomography
(HRCT). HRCT is a sensitive technique for the evaluation
of the presence and severity of emphysema. In patients
with emphysema the densitometric parameters differ sub-
stantially from the corresponding values in patients with
chronic bronchitis and healthy control subjects. Five thin-
section CT scans were obtained in each patient: two scans
of the upper, two scans of the lower lung zones at 3 and 6
cm above and below the carina and one scan at the carina.
The severity and extent of emphysema of each scan was
visually scored on a four-point scale independently by
two observers according to the direct observational
method of Sakai [19]. For each of the lung sections, the
score for the severity of emphysema was multiplied by the
score for the extent and the resultant scores were subse-
quently summed to give a total HRCT score. Visual scores
ranged from 0 (no emphysema) to 120 (severe emphy-
sema). Patients with a score < 30 were subtyped as chronic
bronchitis and patients with a score ≥ 30 were subtyped as
emphysema. According to this assessment the 52 patients
with COPD were divided into 29 patients with chronic
bronchitis and 23 patients with emphysema.
Collection and analysis of laboratory and inflammatory 
parameters
Blood samples were collected in the morning, between
8.30 and 9.30 AM, when patients were in the fasting state
for at least 10 h twice in COPD patients (on hospital
admission-Day 1, and 15 days later- Day 15) and once in
healthy individuals. For the measurement of TNF-α, IL-
1β, IL-6, IL-8, leptin and IGF-I, blood was collected in
plastic tubes containing ethylenediamine-tetraacetic acid
(EDTA) and was centrifuged (1,000 × g for 10 min) within
an hour. The supernatants were stored at -70°C until anal-
ysis. Cytokines (TNF-α, IL-1β, IL-6, IL-8) were measured
with ELISA (BMS 223/3, BMS 224, BMS 213/2 and BMS
204, Bender MedSystems, MedSystems Diagnostics
GmbH, Vienna, Austria Europe, respectively). Leptin and
IGF-I were measured with radioimmunoassay (RIA, Active
Human Leptin IRMA DSL – 23100, Diagnostic Systems
Laboratories, Inc., USA and IGF-I 100 T KIT – Catalog No.
40-2100, Nichols Institute Diagnostics, USA, respec-
tively). The lower detection limit of leptin was 0.10 ng/ml.
The intra- and interassay variation coefficient were 4.9
and 6.6% respectively. The lower detection limit of IF-I
was 0.06 ng/ml. The intra- and interassay coefficient were
3% and 9.8% respectively. All measured values for leptin
and IGF-I were above the lower detection limit.
Statistical analysis
Data were expressed as mean ± SD or as median (25–75
percentile) if they were not normally distributed. Statisti-
cal analysis was performed using nonparametric tests
(Mann-Whitney U test for comparison between groups
and Wilcoxon for comparison within groups). Dichot-
omized Δ was calculated by the formula Δ = D15-D1.
Therefore  ΔTNF-α = TNF-αD1-TNF-αD15,  ΔLeptin =
LeptinD1-LeptinD15 etc. The relations between continu-
ous variables were evaluated with Spearman's rank corre-
lation technique. Statistical significance was accepted at p
< 0.05. Data were analysed using SPSS (Statistical Package
for the Social Sciences, version 14.0 for Windows, SPSS
Inc, Chicago, IL).
Results
Study group
The mean age of COPD patients was 65.8 ± 8.3 years and
the control group 65.9 ± 9.6 years. Clinical characteristics
of the COPD patients (on admission-Day 1) and the
healthy controls are given in Table 1.
Patients with COPD had significantly lower body weight,
BMI and fat mass than did the control subjects. The COPD
patients had severe airflow limitation, decreased PaO2 and
increased PaCO2values. The control subjects had normal
% FVC and % FEV1 on spirograms.
Course of the parameters during the exacerbation
Inflammatory parameters
Compared to their concentrations in the healthy subjects,
TNF-α, IL-1β, IL-6 and IL-8 were significantly higher in the
patients with COPD on D1. By Day 15 cytokine levels did
not differ from those of healthy controls with the excep-
tion of IL-8. Although IL-8 levels were decreased on D15
in COPD patients, they still significantly differed from
healthy subjects (Table 2).
In COPD patients hospitalized due to an acute exacerba-
tion, TNF-α, IL-1β, IL-6 and IL-8 levels on D1 were signif-
icantly higher compared to the levels measured on D15
(Table 2).BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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When COPD patients who received oxygen therapy were
compared to those who did not, no difference in cytokine
levels was detected.
Leptin
The levels of leptin in COPD patients with exacerbation
were significantly higher on D1 and still on D15 com-
pared to healthy subjects [33.3 (16.7–45.5)] ng/ml, p <
0.0001 and [15.7 (8.5–26)] ng/ml, p = 0.022 respectively,
versus [9.6 (4.5–13.7)] ng/ml). Leptin concentration
decreased significantly from D1 to D15 of the COPD exac-
erbation (p < 0.0001). After dividing leptin by %FM, the
same pattern was seen. Thus, leptin/%FM was signifi-
cantly elevated on D1 and nearly significantly increased
Table 1: Characteristics of the two groups
COPD patients (n = 52)
43 M, 9 F
(Mean ± SD)
Healthy subjects (n = 25)
19 M, 6 F
(Mean ± SD)
p
Age, yr 65,8 ± 8,3 65.9 ± 9.6 0.789
Weight, kg 71,1 ± 13,6 77.2 ± 10.1 0.037
Height, cm 166,48 ± 7,11 167.56 ± 6.91 0.669
BMI, kg/m2 25,6 ± 4,1 27.9 ± 4.1 0.029
Fat mass, kg 21,5 ± 6,6 25.9 ± 7.3 0.011
Fat free mass, kg 49,6 ± 9,0 51,2 ± 7,9 0.427
% FM 29,8 ± 5,1 31.6 ± 6.3 0.211
FVC %Pred 62,4 ± 14,3 92.6 ± 6.6 0.000
FEV1%Pred 44,1 ± 11,4 89.9 ± 8.0 0.000
PaO2mmHg 58,2 ± 12,5 87.6 ± 4.6 0.000
PaCO2mmHg 47,1 ± 10,8 39.2 ± 2.5 0.000
Table 2: Concentrations of plasma cytokines, leptin and IGF-I in healthy controls compared to patients with COPD exacerbation on 
admission to the hospital (D1) and after two weeks (D15)
Markers
Median (25–75 percentile)
COPD patients (D1)
(n = 52)
Healthy subjects
(n = 25)
COPD patients
(D15)
(n = 52)
TNF-α (pg/ml) 63.9(46.7–84.5)* †† 14 (9.2–15.8) 14.3 (10.5–19.9)
IL-1β (pg/ml) 12.5 (8.8–16.9) * †† 3.6 (2.6–4) 3.8 (2.7–5.2)
IL-6 (pg/ml) 23 (17.7–44.6) * †† 9.7 (7.5–12.3) 10.6 (6.5–14.9)
IL-8 (pg/ml) 39.8 (29.2–56.3) * †† 13.7 (10–19) 18.5 (12.3–24) †
Leptin (ng/ml) 33.3 (16.7–45.5) * †† 9.6 (4.5–13.7) 15.7 (8.5–26) †
IGF-1 (ng/ml) 59.7 (44.3–76) * †† 133.2 (124–164.5) 96.6 (82.9–116.8) *
Leptin/% FM 1.1 (0.6–1.55) * †† 0.30 (0.16–0.43) 0.5 (0.26–0.94) *
Between healthy subjects and COPD patients * p < 0.01 † p < 0.05
Between COPD patients D1 and D15 †† p < 0.01BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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on D15 compared to healthy subjects (p <0.001 and p =
0.008 respectively).
Insulin-like growth factor I (IGF-I)
Compared to its concentration in the healthy subjects
[133.2 (124–164.5)] ng/ml), plasma IGF-I was signifi-
cantly lower in COPD patients on D1 of the exacerbation
and remained lower on D15 [59.7 (44.3–76)] ng/ml, p
<0.001 and [96.6 (82.9–116.8)] ng/ml, p < 0.001 respec-
tively versus healthy subjects). IGF-I levels were signifi-
cantly increased from D1 to D15 throughout the
exacerbation (p < 0.001).
Chronic bronchitis and emphysema
Characteristics of the study group stratified into the
COPD subtypes (23 patients with emphysema and 29
patients with chronic bronchitis) are given in Table 3.
Patients with emphysema were characterized by a signifi-
cantly lower FVC and FEV1 compared to those with
chronic bronchitis. Emphysematous patients had also a
significantly lower BMI owing to a significantly lower FM
(mean difference 5.04 kg). No difference was found in
PaO2 and PaCO2 between patients with chronic bronchitis
and emphysema.
No differences were seen in the concentrations of TNF-α,
IL-1β, IL-6, IL-8, leptin and leptin/% FM between the two
groups of patients on D1 and D15. On the contrary, IGF-
I was significantly lower in emphysematous patients com-
pared to patients with chronic bronchitis both on D1 and
D15 [49.5 (40.1–65.4)] versus [70.5 (48.6–78.5)] ng/ml,
p = 0.003 on D1 and [84.7 (74.4–96.9)] versus [112.7
(92.4–124.1)] ng/ml, p < 0.001 on D15) (Table 4 and
Table 5, Figure 1).
Correlation analyses
A strong correlation between leptin and % FM was
observed in controls (r = 0.780, p < 0.001).
In order to elucidate the possible relationship of circulat-
ing cytokine levels with plasma leptin and IGF-I concen-
trations correlation analysis was performed on D1 and
D15.
On D1 of the exacerbation, TNF-α demonstrated a signif-
icant positive correlation with leptin as well as with leptin
adjusted to % FM (r = 0.620, p < 0.001 and r = 0.650, p <
0.001)(Figure 2). This correlation between TNF-α and
leptin was true even when we studied patients with
chronic bronchitis and emphysema separately (r = 0.719,
p < 0.001 and r = 0.505, p = 0.014 respectively). TNF-α
was also positively correlated with leptin/% FM in both
chronic bronchitis and emphysema (r = 0.774, p < 0.001
and r = 0.499, p = 0.015 respectively). Moreover, the
change in TNF-α levels (ΔTNF-α) was significantly related
to the change in leptin levels (ΔLeptin) (r = 0.545, p <
0.001).
On D15, no significant correlations could be revealed
between any of the parameters.
IGF-I was not found to be related to any of the inflamma-
tory cytokines neither on D1 nor on D15.
Discussion
The present study was performed to examine circulating
levels of leptin and IGF-I at the onset of COPD exacerba-
tions (D1) and two weeks later (D15) and furthermore to
investigate the relationship of plasma leptin and IGF-I
concentrations with cytokine concentrations as a possible
reflection of the enhanced inflammatory status observed
during the COPD exacerbation.
We found that COPD exacerbations are characterized by
increased levels of leptin and the proinflammatory
cytokines TNF-α, IL-1β, IL-6 and IL-8 and decreased levels
of IGF-I on D1. We also found that two weeks after the
onset of the exacerbation (D15) cytokine levels did not
significantly differ from those of healthy subjects, with the
exception of IL-8. IL-8 levels, although significantly
decreased in COPD patients between D1 and D15, they
still remained higher on D15 compared to healthy sub-
Table 3: Characteristics of patients with chronic bronchitis and 
emphysema
Chronic bronchitis
(n = 29)
25 M, 4 F
Emphysema
(n = 23)
18 M, 5 F
p
Age, yr 68.9 ± 9.3 70.8 ± 7.0 0.524
Weight, kg 75.3 ± 14.1 65.9 ± 11.4 0.022
Height, cm 166.44 ± 7.10 166.52 ± 7.29 0.971
BMI, kg/m2 27.1 ± 4.2 23.7 ± 3.1 0.003
% FM 31.4 ± 4.5 27.9 ± 5.2 0.047
Fat mass, kg 23.7 ± 6.4 18.7 ± 5.7 0.006
Fat free mass, kg 51,5 ± 9,7 47,2 ± 7,7 0.058
FVC %Pred 65.7 ± 14.1 58.1 ± 13.8 0.032
FEV1%Pred 47.4 ± 11.2 39.2 ± 9.9 0.005
PaO2mmHg 59,4 ± 13,3 56,6 ± 11,6 0.256
PaCO2mmHg 49,6 ± 12,0 41,1 ± 9,5 0.276BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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jects. Although circulating plasma leptin decreases and
plasma IGF-I increases, they still remained different com-
pared to healthy controls on D15. Leptin was positively
related to TNF-α on D1 of the exacerbation and this corre-
lation also applied to both subgroups of COPD patients,
thus chronic bronchitis and emphysema. Finally, we
found that IGF-I levels were significantly lower to emphy-
sematous patients compared to patients with chronic
bronchitis both on D1 and on D15. Leptin and cytokine
levels did not differ between patients with chronic bron-
chitis and emphysema.
The elevated levels of TNF-α, IL-1β, IL-6 and IL-8 on
admission to the hospital (D1), observed in our study are
in keeping with numerous studies that have reported
increased levels of circulating cytokines in the peripheral
circulation of patients with COPD [3,20,21]. These abnor-
malities, albeit seen in clinically stable COPD patients,
IGF-I in chronic bronchitis (B), emphysema (E) and control group (C) on admission to the hospital (D1) Figure 1
IGF-I in chronic bronchitis (B), emphysema (E) and control group (C) on admission to the hospital (D1). Signifi-
cant differences between B-E (p = 0.003), B-C (p = 0.000) and E-C (p = 0.000)BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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they are generally more pronounced during exacerbations
of the disease [21]. The systemic inflammatory response is
ameliorated 15 days after the onset of the exacerbation, as
shown by the decrease in cytokine levels.
Circulating leptin levels were high on D1 of the exacerba-
tion and remained elevated on D15 in COPD patients
compared to healthy subjects. The elevated leptin concen-
trations during COPD exacerbation are in keeping with
the results of other studies [7] and likely represented an
up-regulation of leptin mRNA resulting in an enhanced
leptin production that might have been induced by sev-
eral factors. The positive correlation between leptin and
TNF-α which was seen in our COPD patients on D1 of the
exacerbation, supports an inflammatory-related distur-
bance in leptin metabolism in COPD. This correlation
was true even when we studied separately the two sub-
groups of patients (chronic bronchitis – emphysema). It
has been shown that the administration of endotoxin or
cytokines such as TNF-α and IL-1 can increase serum lep-
tin levels both in hamsters and humans [8,9]. A positive
correlation between leptin and soluble TNF-α receptors
(sTNF-R55) was also found during COPD exacerbations
in the study by Creutzberg et al [7]. In a recent study by
Calikoglu et al serum leptin and TNF-α levels were
increased in COPD patients with exacerbation in compar-
ison to COPD patients with stable disease and healthy
controls [22]. Moreover, and in accordance with our find-
ings, a strong correlation between TNF-α and leptin was
observed only in COPD patients with exacerbation but
not in stable COPD patients and healthy individuals [22].
Takabatake et al recently reported that serum leptin levels
Table 4: Concentrations of plasma cytokines, leptin and IGF-I in patients with chronic bronchitis and emphysema on admission to the 
hospital (D1).
Markers
Median (25–75 percentile)
Chronic bronchitis
(n = 29)
Emphysema
(n = 23)
p
TNF-α (pg/ml) 63.2 (45.5–85.7) 65 (47.2–80.2) 0.612
IL-1β (pg/ml) 12.6 (8.8–15.6) 12.3 (8.4–21.3) 0.941
IL-6 (pg/ml) 23.9 (19.7–40.4) 20.6 (15.9–52.6) 0.423
IL-8 (pg/ml) 39.7 (28.9–56.2) 42 (34.3–62.7) 0.574
Leptin (ng/ml) 37.7 (18.1–50.9) 32.5 (15.2–44.9) 0.214
IGF-1 (ng/ml) 70.5 (48.6–78.5) 49.5 (40.1–65.4) 0.003
Leptin/% FM 1.1 (0.62–1.61) 1.09 (0.6–1.55) 0.619
Table 5: Concentrations of plasma cytokines, leptin and IGF-I in patients with chronic bronchitis and emphysema on D15.
Markers
(Median (25–75 percentile)
Chronic bronchitis
(n = 29)
Emphysema
(n = 23)
p
TNF-α (pg/ml) 13.7 (10.5–19.8) 15.1 (10.5–20.1) 0.632
IL-1β (pg/ml) 3.9 (3.4–5.8) 3.7 (2–4.7) 0.273
IL-6 (pg/ml) 10.6 (7.4–14.1) 10.4 (5.8–16.2) 0.706
IL-8 (pg/ml) 17.9 (11.8–23.2) 19 (12.3–26.6) 0.612
Leptin (ng/ml) 15.6 (7.9–28.6) 15.7 (8.4–22.8) 0.847
IGF-1 (ng/ml) 112.7 (92.4–124.1) 84.7 (74.4–96.9) 0.000
Leptin/% FM 0.45 (0.27–0.98) 0.56 (0.25–0.81) 0.768BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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were significantly lower in COPD patients than healthy
controls [23]. However, this study included patients with
stable disease who were free of symptoms for at least three
months. The relationship between the change in TNF-α
levels (ΔTNF-α) and the change in leptin levels (ΔLeptin)
observed in our study, further supports a TNF-α-related
disturbance in leptin during COPD exacerbations.
A reason for the high leptin concentrations might have
been the glucocorticosteroid treatment and that presents a
limitation of our study. Reports concerning the effects of
corticosteroids on leptin are contradictory. Two days of
oral dexamethasone (1.5 mg/day) in healthy subjects
resulted in significantly increased serum concentrations of
leptin [24]. In another study, administration of dexameth-
asone for 4 days (2.5 mg/day) to healthy subjects also
induced a significant increase in plasma leptin concentra-
tions [25]. Glucocorticosteroids may have a stimulating
effect on leptin via the induction of insulin resistance, as
glucose and insulin are also able to induce leptin expres-
sion [26]. However, Tataranni et al demonstrated that
acute intravenous administration of glucocorticosteroids
or prolonged oral treatment did not affect serum leptin
levels [27]. Our COPD patients had severe airflow
obstruction and it was necessary to introduce steroid treat-
ment to improve their clinical status. However, samples
on D1 were obtained before the first corticosteroid
administration and on D15 7 days after the last intrave-
nous administration of prednisolone, according to the
protocol used. Regarding the effects of adrenergic stimula-
tion on leptin metabolism, no studies have been per-
formed with specific β2-adrenergic stimulants such as
Leptin is significantly related to TNF-α in COPD patients on Day 1 of the exacerbation Figure 2
Leptin is significantly related to TNF-α in COPD patients on Day 1 of the exacerbation.BMC Pulmonary Medicine 2009, 9:11 http://www.biomedcentral.com/1471-2466/9/11
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salbutamol. Intravenous infusion of isoprenaline in
young healthy volunteers resulted in a maximal suppres-
sion of plasma leptin of 20% of baseline values after 2 h,
but in the recovery period of 1 h, leptin concentrations
rapidly returned to normal [28]. In our study COPD
patients received salbutamol by nebulizer and not intrave-
nously.
Limited data is available regarding circulating levels of
IGF-I in COPD. Growth hormone (GH) mediates its
major metabolic effects predominantly through IGF-I
[10]. The GH axis is suppressed in chronic diseases and
this may partly explain the low IGF-I levels. However,
increased concentrations of GH have been found in
COPD patients, especially in those with hypoxaemia [29].
In our study, patients with COPD exacerbation had signif-
icantly lower IGF-I levels on D1 and also on D15 com-
pared to healthy controls. Our finding of low IGF-I levels
is compatible with other studies. Casaburi et al have also
reported low levels of IGF-I in COPD patients [30]. Spruit
et al found that IGF-I levels tended to be lower in patients
with COPD exacerbation than in healthy subjects [12].
We are aware that the bioavailability and the effects of
IGF-I are influenced by IGF-I binding proteins (IGFBP).
Therefore, an increase in circulating levels of these pro-
teins may decrease the levels of free IGF-I [31]. Cytokines
increase IGFBP-1 and IGFBP-4 and this results in a
decreased free IGF-I fraction. IL-6 performs its suppressive
activity on IGF-I via increased production of its binding
protein [32].
It is interesting to note that IGF-I levels were lower in
patients with emphysema compared to those with chronic
bronchitis, both at the onset of the exacerbation and 15
days later, whereas cytokine and leptin levels did not dif-
fer between the two subgroups. The decline in IGF-I levels
may itself be deleterious. IGF-I mRNA levels were
decreased in muscle biopsies from hospitalized patients
due to an acute exacerbation of COPD [13]. Moreover, it
has been demonstrated that pulmonary rehabilitation
leads to an increase in muscle mRNA expression of IGF-I
in COPD patients [33]. COPD patients often present with
hypoxia during exacerbations. In animal studies, recom-
binant IGF-I has been shown to ameliorate the protein
catabolism observed under hypoxic conditions and to
promote anabolism [14]. The decreased levels of this ana-
bolic factor, especially in emphysematous patients further
enhance its possible role in metabolic derangements of
COPD and mainly emphysema. The lower body weight,
usually observed in patients with emphysema may be
related to the lower IGF-I levels found in these patients,
particularly during exacerbations. Low levels of anabolic
hormones could act synergistically with the catabolic
activity of cytokines and leptin and play a role in the
weight loss and decreased muscular mass usually seen in
COPD patients and mainly those with emphysema. This
may also have important therapeutic implications, since
an increase in anabolic factors in COPD patients, particu-
larly during exacerbations may have a protective meta-
bolic effect.
Conclusion
During an acute exacerbation of COPD, elevated levels of
the proinflammatory cytokines TNF-α, IL-1β, IL-6 and IL-
8 and increased levels of leptin and decreased levels of
IGF-I are observed. It seems that, although systemic
inflammation, in terms of cytokines, is restored relatively
quickly, the coexistent disturbance of leptin and IGF-I is
preserved for a longer period of time.
Lower levels of the anabolic factor IGF-I are observed in
emphysema compared to chronic bronchitis and this may
be related to the more pronounced metabolic derange-
ments observed in this subgroup. Further studies are
needed to elucidate the role of increased leptin and
decreased IGF-I levels during COPD exacerbations and
their possible relationship with energy imbalance
observed in these patients.
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